Aqua Bio Technology Asa · OSL:ABTEC
Aqua Bio Technology Asa — Q3 2015 Earnings Presentation
11 slides from Aqua Bio Technology Asa's earnings presentation, Nov 18, 2015
Slide 1: Third Quarter 2015 Results Presentation
Third Quarter 2015 Results Presentation 18 November 2015 1
Slide 2: Q3 2015 Highlights
Q3 2015 Highlights • Revenue stream according to exclusivity contracts • Continued good profitability • Historically strong cash position – NOK 35.2 million cash reserve
Slide 3: Income Statement
Income Statement NOK million Q3 2015 Q3 2014 YTD 2015 YTD 2014 Income 10.5 6.7 28.6 17.3 Operating costs -5.5 -3.1 -13.7 -12.7 EBITDA 5.0 3.6 14.9 4.6 EBIT 3.4 2.0 10.1 -0.2 EBT 2.9 2.1 10.2 0.0 Net result 2.9 2.1 10.2 0.0 EBITDA margin 47.6% 53.7% 52.1% 26.6% • Royalty and exclusivity payments rece
Slide 4: Income and results development
Income and results development NOK 1.000 6000 70,0 % 12000 5000 60,0 % 10000 50,0 % 4000 8000 40,0 % 3000 6000 30,0 % 2000 4000 20,0 % 1000 10,0 % 2000 0 0,0 % 0 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 -1000 -10,0 % Andre inntekter Salgsinntekter EBITDA (NOK 1,000) EB
Slide 5: Strongest cash position ever
Strongest cash position ever NOK mill 40 • NOK 35.2 million cash and cash equivalents as of 30 September 2015 35 • ABT first dividend payments Q2 2015 30 (NOK 6.4 million) 25 20 15 10 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 13 13 13 13 14 14 14 14 15 15 15 5
Slide 6: Balance Sheet
Balance Sheet NOK million 30 Sep 2015 31 Dec 2014 30 Sep 2014 Fixed assets 9.7 12.4 14.0 Current assets 68.7 63.4 60.9 - of which is cash 35.2 29.2 27.0 Total equity 69.5 66.3 66.1 Long term debt 5.3 5.6 7.1 Short term debt 3.5 3.9 1.7 Total balance 78.4 75.8 74.9 Equity ratio 88.7% 73.8% 88.2%
Slide 7: Cash flow
Cash flow NOK million (Year to date) 2015 2014 Cash at beginning of period 29.2 27.0 From operations 14.9 4.2 From investments -2.2 -2.3 From financing -7.3 -1.9 Currency effects 0.5 0.0 Cash at end of period 35.2 27.0 Cash change in period 5.5 0.0 • ABT paid its shareholders a total of NOK 6.4 mill
Slide 8: A strategy for expansion
A strategy for expansion 1. Support exclusivity partners Restorsea and Amway in their efforts to Ongoing reach commercial success in the cosmetics market with skin care products based on ABT technology. 2. Active in-licensing of relevant technologies from partners; develop Ongoing ABT as a powerhous
Slide 9: Outlook
Outlook • Continued strong revenue stream – Contracted revenue and exclusivity and royalty payments until 2017 – Commercial success of exclusivity partners represent upside potential • Strategy of broadened market approach holds potential – Search, and evaluation of in-licensing candidates continues
Slide 10: 4th Quarter and Full Year 2015 Results 10 February 2016
4th Quarter and Full Year 2015 Results 10 February 2016
Slide 11: Investor contact
Investor contact Arvid Lindberg, CEO +47 9824 5410 arvid@aquabiotech.no www.aquabiotechnology.com